United States Biotechnology & Medical Research

CytomX Therapeutics Inc (CTMX)

Track

Over the past 90 days, CytomX Therapeutics Inc. recorded one insider transaction, consisting of a $4,953 sale by the Chief Financial Officer. This follows a period of broader executive selling earlier in the year. The stock has declined 26% over the last quarter, coinciding with a recent earnings report that missed expectations.
Ticker: CTMX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for CytomX Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Ogden Christopher
Chief Financial Officer
1 sale — total 4,953 USD
Sale 15 Jun 2026
Value US$4,413,054.98 | Price 395.28 | Shares 20,899
Sale 17 Mar 2026
Value US$2,742,863.58 | Price 150.04 | Shares 4,844
Sale 17 Mar 2026
Value US$764,137.89 | Price 6.42 | Shares 118,969
Sale 17 Mar 2026
Value US$202,273.12 | Price 6.42 | Shares 31,492
Sale 17 Mar 2026
Value US$124,111.63 | Price 6.42 | Shares 19,323
Planned sale 6 Nov 2025
Value US$461,906.10 | Price 4.54 | Shares 101,793
Proposed sale 6 Nov 2025
Value US$461,909.00 | Price 4.54 | Shares 101,793
Sale 16 Jun 2025
Value US$28,539.98 | Price 2.69 | Shares 10,614
Sale 16 Jun 2025
Value US$37,334.08 | Price 2.69 | Shares 13,884
Sale 16 Jun 2025
Value US$149,263.53 | Price 2.69 | Shares 55,511
Sale 13 Jun 2025
Value US$4,841.44 | Price 2.95 | Shares 1,641
Sale 18 Mar 2025
Value US$6,111.60 | Price 0.60 | Shares 10,203
Sale 18 Mar 2025
Value US$22,555.94 | Price 0.60 | Shares 37,656
Sale 18 Mar 2025
Value US$11,687.69 | Price 0.60 | Shares 19,512
Sale 18 Mar 2025
Value US$5,122.05 | Price 0.60 | Shares 8,551
Sale 18 Mar 2025
Value US$2,410.98 | Price 0.60 | Shares 4,025
Sale 20 Aug 2024
Value US$5,138.87 | Price 1.23 | Shares 4,181
Sale 20 Aug 2024
Value US$17,082.03 | Price 1.23 | Shares 13,898
Sale 20 Aug 2024
Value US$2,438.53 | Price 1.23 | Shares 1,984
Sale 20 Aug 2024
Value US$5,138.87 | Price 1.23 | Shares 4,181
Sale 20 Aug 2024
Value US$5,138.87 | Price 1.23 | Shares 4,181
Sale 19 Mar 2024
Value US$10,986.41 | Price 2.09 | Shares 5,268
Sale 19 Mar 2024
Value US$26,683.97 | Price 2.09 | Shares 12,795
Sale 19 Mar 2024
Value US$13,685.05 | Price 2.09 | Shares 6,562
Sale 19 Mar 2024
Value US$42,175.07 | Price 2.09 | Shares 20,223
Sale 19 Mar 2024
Value US$6,196.02 | Price 2.09 | Shares 2,971
Sale 20 Dec 2023
Value US$2,747.39 | Price 1.38 | Shares 1,990
Sale 20 Dec 2023
Value US$18,709.87 | Price 1.38 | Shares 13,551
Sale 20 Dec 2023
Value US$5,628.30 | Price 1.38 | Shares 4,077
Sale 20 Dec 2023
Value US$5,629.11 | Price 1.38 | Shares 4,077
Sale 20 Dec 2023
Value US$5,628.30 | Price 1.38 | Shares 4,077
Sale 22 Sep 2023
Value US$7,135.09 | Price 1.30 | Shares 5,486
Sale 22 Sep 2023
Value US$5,355.94 | Price 1.30 | Shares 4,119
Sale 22 Sep 2023
Value US$18,987.14 | Price 1.30 | Shares 14,601
Sale 22 Sep 2023
Value US$5,355.94 | Price 1.30 | Shares 4,119
Sale 16 Mar 2023
Value US$2,923.28 | Price 1.98 | Shares 1,477
Sale 16 Mar 2023
Value US$4,031.22 | Price 1.98 | Shares 2,037
Sale 16 Mar 2023
Value US$13,391.04 | Price 1.88 | Shares 7,121
Sale 16 Mar 2023
Value US$3,459.47 | Price 1.98 | Shares 1,748
Sale 16 Mar 2023
Value US$8,424.60 | Price 1.98 | Shares 4,257
Sale 16 Mar 2023
Value US$1,021.32 | Price 1.98 | Shares 516
Sale 20 Jul 2022
Value US$5,981.77 | Price 1.42 | Shares 4,206
Sale 20 Jul 2022
Value US$10,612.39 | Price 1.42 | Shares 7,463
Sale 20 Jul 2022
Value US$7,965.48 | Price 1.42 | Shares 5,602
Sale 20 Jul 2022
Value US$5,617.06 | Price 1.42 | Shares 3,949
Sale 20 Jul 2022
Value US$7,967.72 | Price 1.42 | Shares 5,602
Sale 20 Jul 2022
Value US$21,206.42 | Price 1.42 | Shares 14,911
Planned sale 16 Jun 2021
Value US$704,470.00 | Price 7.04 | Shares 100,000
Planned sale 31 Mar 2021
Value US$749,470.00 | Price 7.49 | Shares 100,000
Planned sale 12 May 2020
Value US$540,000.00 | Price 15.00 | Shares 36,000
Buy 4 Mar 2019
Value US$92,970.00 | Price 10.33 | Shares 9,000
Planned sale 12 Dec 2018
Value US$45,000.00 | Price 15.00 | Shares 3,000
Planned sale 2 Nov 2018
Value US$17,348.09 | Price 15.01 | Shares 1,156
Planned sale 1 Nov 2018
Value US$79,050.00 | Price 15.00 | Shares 5,270
Planned sale 1 Nov 2018
Value US$1,500.50 | Price 15.01 | Shares 100
Planned sale 1 Nov 2018
Value US$45,000.00 | Price 15.00 | Shares 3,000
Planned sale 1 Oct 2018
Value US$55,380.00 | Price 18.46 | Shares 3,000
Planned sale 4 Sep 2018
Value US$285,342.82 | Price 21.86 | Shares 13,052
Planned sale 4 Sep 2018
Value US$67,170.00 | Price 22.39 | Shares 3,000
Planned sale 1 Aug 2018
Value US$78,150.00 | Price 26.05 | Shares 3,000
Planned sale 5 Jul 2018
Value US$112,688.52 | Price 25.06 | Shares 4,497
Planned sale 3 Jul 2018
Value US$50,880.49 | Price 25.09 | Shares 2,028
Planned sale 2 Jul 2018
Value US$305,707.86 | Price 23.42 | Shares 13,052
Planned sale 2 Jul 2018
Value US$67,680.00 | Price 22.56 | Shares 3,000
Planned sale 1 Jun 2018
Value US$77,793.00 | Price 25.93 | Shares 3,000
Planned sale 1 May 2018
Value US$519,743.04 | Price 26.55 | Shares 19,578
Planned sale 1 May 2018
Value US$79,562.10 | Price 26.52 | Shares 3,000
Planned sale 2 Apr 2018
Value US$84,360.00 | Price 28.12 | Shares 3,000
Planned sale 26 Mar 2018
Value US$159,641.50 | Price 31.93 | Shares 5,000
Planned sale 2 Mar 2018
Value US$485,465.60 | Price 30.00 | Shares 16,181
Planned sale 2 Mar 2018
Value US$484,800.00 | Price 30.00 | Shares 16,160
Planned sale 2 Mar 2018
Value US$60,293.16 | Price 31.02 | Shares 1,944
Planned sale 2 Mar 2018
Value US$381,384.35 | Price 30.41 | Shares 12,541
Planned sale 2 Mar 2018
Value US$165,775.38 | Price 30.06 | Shares 5,515
Planned sale 1 Mar 2018
Value US$576,141.38 | Price 29.43 | Shares 19,578
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-17 2026-06-15 S Sale
4.1
Ogden Christopher

Chief Financial Officer

Officer
20,899 -9.6%
395.28
US$4,413,055 		20,899 -9.6% 395.28 US$4,413,055
2026-03-19 2026-03-17 S Sale
4.0
Chu Yu-Waye

Chief Medical Officer

Officer
4,844 +25.3%
150.04
US$2,742,864 		4,844 +25.3% 150.04 US$2,742,864
2026-03-19 2026-03-17 S Sale
4.2
McCarthy Sean A.

CEO

Executive Director
57,559 -18.1%
90.40
US$2,536,683 		57,559 -18.1% 90.40 US$2,536,683
2026-03-19 2026-03-17 S Sale
4.1
BELVIN MARCIA

SVP, Chief Scientific Officer

Officer
31,492 -9.5%
6.42
US$202,273 		31,492 -9.5% 6.42 US$202,273
2026-03-19 2026-03-17 S Sale
4.1
Ogden Christopher

Chief Financial Officer

Officer
19,323 -6.1%
6.42
US$124,112 		19,323 -6.1% 6.42 US$124,112
2025-11-10 2025-11-06 PlS Planned sale
4.2
McCarthy Sean A.

CEO

Executive Director
101,793 -9.3%
4.54
US$461,906 		101,793 -9.3% 4.54 US$461,906
2025-11-06 2025-11-06 PrS Proposed sale
4.2
Sean McCarthy

CEO
101,793
4.54
US$461,909 		101,793 4.54 US$461,909
2025-06-17 2025-06-16 S Sale
4.1
Ogden Christopher

Chief Financial Officer

Officer
10,614 -4.5%
2.69
US$28,540 		10,614 -4.5% 2.69 US$28,540
2025-06-17 2025-06-16 S Sale
4.1
BELVIN MARCIA

SVP, Chief Scientific Officer

Officer
13,884 -4.9%
2.69
US$37,334 		13,884 -4.9% 2.69 US$37,334
2025-06-17 2025-06-16 S Sale
4.2
McCarthy Sean A.

CEO

Executive Director
55,511 -4.8%
2.69
US$149,264 		55,511 -4.8% 2.69 US$149,264
2025-06-17 2025-06-13 S Sale
4.1
Ogden Christopher

Chief Financial Officer

Officer
1,641 -0.8%
2.95
US$4,841 		1,641 -0.8% 2.95 US$4,841
2025-03-20 2025-03-18 S Sale
2.3
ROWLAND LLOYD A

General Counsel

Officer
10,203 -7.8%
0.60
US$6,112 		10,203 -7.8% 0.60 US$6,112
2025-03-20 2025-03-18 S Sale
4.2
McCarthy Sean A.

CEO

Executive Director
37,656 -3.6%
0.60
US$22,556 		37,656 -3.6% 0.60 US$22,556
2025-03-20 2025-03-18 S Sale
4.1
BELVIN MARCIA

SVP, Chief Scientific Officer

Officer
19,512 -7.3%
0.60
US$11,688 		19,512 -7.3% 0.60 US$11,688
2025-03-20 2025-03-18 S Sale
4.1
Ogden Christopher

Chief Financial Officer

Officer
8,551 -4.1%
0.60
US$5,122 		8,551 -4.1% 0.60 US$5,122
2025-03-20 2025-03-18 S Sale
4.0
Chu Yu-Waye

Chief Medical Officer

Officer
4,025 -2.9%
0.60
US$2,411 		4,025 -2.9% 0.60 US$2,411
2024-08-22 2024-08-20 S Sale
3.4
Landau Jeffrey B

Chief Business Officer

Officer
4,181 -3.4%
1.23
US$5,139 		4,181 -3.4% 1.23 US$5,139
2024-08-22 2024-08-20 S Sale
4.2
McCarthy Sean A.

CEO

Executive Director
13,898 -2.1%
1.23
US$17,082 		13,898 -2.1% 1.23 US$17,082
2024-08-22 2024-08-20 S Sale
4.1
Ogden Christopher

Chief Financial Officer

Officer
1,984 -1.8%
1.23
US$2,439 		1,984 -1.8% 1.23 US$2,439
2024-08-22 2024-08-20 S Sale
2.3
ROWLAND LLOYD A

General Counsel

Officer
4,181 -3.1%
1.23
US$5,139 		4,181 -3.1% 1.23 US$5,139
2024-08-22 2024-08-20 S Sale
4.1
BELVIN MARCIA

SVP, Chief Scientific Officer

Officer
4,181 -2.3%
1.23
US$5,139 		4,181 -2.3% 1.23 US$5,139
2024-03-21 2024-03-19 S Sale
2.3
ROWLAND LLOYD A

General Counsel

Officer
5,268 -4.3%
2.09
US$10,986 		5,268 -4.3% 2.09 US$10,986
2024-03-21 2024-03-19 S Sale
4.1
BELVIN MARCIA

SVP, Chief Scientific Officer

Officer
12,795 -7.1%
2.09
US$26,684 		12,795 -7.1% 2.09 US$26,684
2024-03-21 2024-03-19 S Sale
3.4
Landau Jeffrey B

Chief Business Officer

Officer
6,562 -5.6%
2.09
US$13,685 		6,562 -5.6% 2.09 US$13,685
2024-03-21 2024-03-19 S Sale
4.2
McCarthy Sean A.

CEO

Executive Director
20,223 -3.7%
2.09
US$42,175 		20,223 -3.7% 2.09 US$42,175
2024-03-21 2024-03-19 S Sale
4.1
Ogden Christopher

SVP, Finance and Accounting

Officer
2,971 -3.4%
2.09
US$6,196 		2,971 -3.4% 2.09 US$6,196
2023-12-22 2023-12-20 S Sale
4.1
Ogden Christopher

SVP, Finance and Accounting

Officer
1,990 -3.9%
1.38
US$2,747 		1,990 -3.9% 1.38 US$2,747
2023-12-22 2023-12-20 S Sale
4.2
McCarthy Sean A.

CEO

Executive Director
13,551 -2.9%
1.38
US$18,710 		13,551 -2.9% 1.38 US$18,710
2023-12-22 2023-12-20 S Sale
3.4
Landau Jeffrey B

Chief Business Officer

Officer
4,077 -4.5%
1.38
US$5,628 		4,077 -4.5% 1.38 US$5,628
2023-12-22 2023-12-20 S Sale
2.3
ROWLAND LLOYD A

General Counsel

Officer
4,077 -4.0%
1.38
US$5,629 		4,077 -4.0% 1.38 US$5,629
2023-12-22 2023-12-20 S Sale
4.1
BELVIN MARCIA

SVP, Chief Scientific Officer

Officer
4,077 -2.6%
1.38
US$5,628 		4,077 -2.6% 1.38 US$5,628
2023-09-22 2023-09-22 S Sale
2.3
ROWLAND LLOYD A

General Counsel

Officer
5,486 -6.4%
1.30
US$7,135 		5,486 -6.4% 1.30 US$7,135
2023-09-22 2023-09-22 S Sale
3.4
Landau Jeffrey B

Chief Business Officer

Officer
4,119 -5.1%
1.30
US$5,356 		4,119 -5.1% 1.30 US$5,356
2023-09-22 2023-09-22 S Sale
4.2
McCarthy Sean A.

CEO

Executive Director
14,601 -3.3%
1.30
US$18,987 		14,601 -3.3% 1.30 US$18,987
2023-09-22 2023-09-22 S Sale
4.1
BELVIN MARCIA

SVP, Chief Scientific Officer

Officer
4,119 -2.7%
1.30
US$5,356 		4,119 -2.7% 1.30 US$5,356
2023-03-20 2023-03-16 S Sale
3.4
Landau Jeffrey B

Chief Financial Officer

Officer
1,477 -2.1%
1.98
US$2,923 		1,477 -2.1% 1.98 US$2,923
2023-03-20 2023-03-16 S Sale
2.3
ROWLAND LLOYD A

General Counsel

Officer
2,037 -2.8%
1.98
US$4,031 		2,037 -2.8% 1.98 US$4,031
2023-03-20 2023-03-16 S Sale
4.2
McCarthy Sean A.

CEO

Executive Director
7,121 -1.8%
1.88
US$13,391 		7,121 -1.8% 1.88 US$13,391
2023-03-20 2023-03-16 S Sale
2.4
Campoy Carlos

Chief Financial Officer

Officer
1,748 -4.4%
1.98
US$3,459 		1,748 -4.4% 1.98 US$3,459
2023-03-20 2023-03-16 S Sale
3.7
Peterson Amy C.

EVP, Chief Development Officer

Officer
4,257 -6.8%
1.98
US$8,425 		4,257 -6.8% 1.98 US$8,425
2023-03-20 2023-03-16 S Sale
4.1
Ogden Christopher

SVP, Finance and Accounting

Officer
516 -1.3%
1.98
US$1,021 		516 -1.3% 1.98 US$1,021
2022-07-21 2022-07-20 S Sale
3.4
Landau Jeffrey B

Chief Business Officer

Officer
4,206 -12.0%
1.42
US$5,982 		4,206 -12.0% 1.42 US$5,982
2022-07-21 2022-07-20 S Sale
3.7
Peterson Amy C.

EVP, Chief Development Officer

Officer
7,463 -10.6%
1.42
US$10,612 		7,463 -10.6% 1.42 US$10,612
2022-07-21 2022-07-20 S Sale
1.3
HANNAH ALISON L.

Chief Medical Officer

Officer
5,602 -14.9%
1.42
US$7,965 		5,602 -14.9% 1.42 US$7,965
2022-07-21 2022-07-20 S Sale
2.4
Campoy Carlos

Chief Financial Officer

Officer
3,949 -9.0%
1.42
US$5,617 		3,949 -9.0% 1.42 US$5,617
2022-07-21 2022-07-20 S Sale
2.3
ROWLAND LLOYD A

General Counsel

Officer
5,602 -11.4%
1.42
US$7,968 		5,602 -11.4% 1.42 US$7,968
2022-07-21 2022-07-20 S Sale
4.2
McCarthy Sean A.

President and CEO

Executive Director
14,911 -4.9%
1.42
US$21,206 		14,911 -4.9% 1.42 US$21,206
2021-06-21 2021-06-16 PlS Planned sale
4.2
McCarthy Sean A.

President and CEO

Executive Director
100,000 -51.8%
7.04
US$704,470 		100,000 -51.8% 7.04 US$704,470
2021-04-02 2021-03-31 PlS Planned sale
4.2
McCarthy Sean A.

President and CEO

Executive Director
100,000 -32.6%
7.49
US$749,470 		100,000 -32.6% 7.49 US$749,470
2020-05-14 2020-05-12 PlS Planned sale
4.2
McCarthy Sean A.

President and CEO

Executive Director
36,000 -29.9%
15.00
US$540,000 		36,000 -29.9% 15.00 US$540,000
2019-03-05 2019-03-04 B Purchase
2.3
ROWLAND LLOYD A

General Counsel

Officer
9,000 +919.3%
10.33
US$92,970 		9,000 +919.3% 10.33 US$92,970
2018-12-14 2018-12-12 PlS Planned sale RAY DEBANJAN

Chief Financial Officer

Officer
3,000 -33.6%
15.00
US$45,000 		3,000 -33.6% 15.00 US$45,000
2018-11-05 2018-11-02 PlS Planned sale McCarthy Sean A.

President and CEO

Executive Director
1,156 -1.4%
15.01
US$17,348 		1,156 -1.4% 15.01 US$17,348
2018-11-05 2018-11-01 PlS Planned sale McCarthy Sean A.

President and CEO

Executive Director
5,270 -6.0%
15.00
US$79,050 		5,270 -6.0% 15.00 US$79,050
2018-11-05 2018-11-01 PlS Planned sale McCarthy Sean A.

President and CEO

Executive Director
100 -0.1%
15.01
US$1,500 		100 -0.1% 15.01 US$1,500
2018-11-05 2018-11-01 PlS Planned sale RAY DEBANJAN

Chief Financial Officer

Officer
3,000 -33.6%
15.00
US$45,000 		3,000 -33.6% 15.00 US$45,000
2018-10-02 2018-10-01 PlS Planned sale RAY DEBANJAN

Chief Financial Officer

Officer
3,000 -33.6%
18.46
US$55,380 		3,000 -33.6% 18.46 US$55,380
2018-09-06 2018-09-04 PlS Planned sale McCarthy Sean A.

President and CEO

Executive Director
13,052 -13.7%
21.86
US$285,343 		13,052 -13.7% 21.86 US$285,343
2018-09-06 2018-09-04 PlS Planned sale RAY DEBANJAN

Chief Financial Officer

Officer
3,000 -33.6%
22.39
US$67,170 		3,000 -33.6% 22.39 US$67,170
2018-08-02 2018-08-01 PlS Planned sale RAY DEBANJAN

Chief Financial Officer

Officer
3,000 -33.6%
26.05
US$78,150 		3,000 -33.6% 26.05 US$78,150
2018-07-09 2018-07-05 PlS Planned sale McCarthy Sean A.

President and CEO

Executive Director
4,497 -5.2%
25.06
US$112,689 		4,497 -5.2% 25.06 US$112,689
2018-07-06 2018-07-03 PlS Planned sale McCarthy Sean A.

President and CEO

Executive Director
2,028 -2.4%
25.09
US$50,880 		2,028 -2.4% 25.09 US$50,880
2018-07-03 2018-07-02 PlS Planned sale McCarthy Sean A.

President and CEO

Executive Director
13,052 -13.7%
23.42
US$305,708 		13,052 -13.7% 23.42 US$305,708
2018-07-03 2018-07-02 PlS Planned sale RAY DEBANJAN

Chief Financial Officer

Officer
3,000 -33.6%
22.56
US$67,680 		3,000 -33.6% 22.56 US$67,680
2018-06-05 2018-06-01 PlS Planned sale RAY DEBANJAN

Chief Financial Officer

Officer
3,000 -33.6%
25.93
US$77,793 		3,000 -33.6% 25.93 US$77,793
2018-05-02 2018-05-01 PlS Planned sale McCarthy Sean A.

President and CEO

Executive Director
19,578 -80.8%
26.55
US$519,743 		19,578 -80.8% 26.55 US$519,743
2018-05-02 2018-05-01 PlS Planned sale RAY DEBANJAN

Chief Financial Officer

Officer
3,000 -38.8%
26.52
US$79,562 		3,000 -38.8% 26.52 US$79,562
2018-04-04 2018-04-02 PlS Planned sale RAY DEBANJAN

Chief Financial Officer

Officer
3,000 -38.8%
28.12
US$84,360 		3,000 -38.8% 28.12 US$84,360
2018-03-27 2018-03-26 PlS Planned sale GLUCK FREDERICK W
5,000 -1.8%
31.93
US$159,642 		5,000 -1.8% 31.93 US$159,642
2018-03-05 2018-03-02 PlS Planned sale GLUCK FREDERICK W
16,181 -5.5%
30.00
US$485,466 		16,181 -5.5% 30.00 US$485,466
2018-03-05 2018-03-02 PlS Planned sale HUMPHREY RACHEL

Chief Medical Officer
16,160 -34.8%
30.00
US$484,800 		16,160 -34.8% 30.00 US$484,800
2018-03-05 2018-03-02 PlS Planned sale RAY DEBANJAN

Chief Financial Officer
1,944 -29.1%
31.02
US$60,293 		1,944 -29.1% 31.02 US$60,293
2018-03-05 2018-03-02 PlS Planned sale RAY DEBANJAN

Chief Financial Officer
12,541 -65.2%
30.41
US$381,384 		12,541 -65.2% 30.41 US$381,384
2018-03-05 2018-03-02 PlS Planned sale RAY DEBANJAN

Chief Financial Officer
5,515 -53.8%
30.06
US$165,775 		5,515 -53.8% 30.06 US$165,775
2018-03-05 2018-03-01 PlS Planned sale McCarthy Sean A.

President and CEO

Executive Director
19,578 -80.8%
29.43
US$576,141 		19,578 -80.8% 29.43 US$576,141
Explore more

More insider trading research around CytomX Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America